Efficacy of Adaptogenic Supplements on Adapting to Stress: A Randomized, Controlled Trial

Hovhannisyan, Areg; Nylander, M.

doi:10.4172/2324-9080.1000205

Cited by 10 publications

(15 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A systematic review of these studies reveals that Rhodiola preparations exhibit ergogenic, antifatigue and antidepressant properties, indicated by an enhancement of both physical and mental performance. Although contradictory results exist in different studies, most studies show that both R. rosea and R. crenulate are able to enhance physical performance in healthy subjects, indicating an ergogenic effect . Several commercially available R. rosea preparations, such as ADAPT‐232, SHR‐5, and WS 1375, are highly evidenced to benefit burnout patients or subjects with work‐ or stress‐related fatigue after repeated doses or a single dose .…”

Section: Clinical Trialsmentioning

confidence: 99%

“…Although contradictory results exist in different studies, 242,243 most studies show that both R. rosea and R. crenulate are able to enhance physical performance in healthy subjects, indicating an ergogenic effect. 219,230 Several commercially available R. rosea preparations, such as ADAPT-232, SHR-5, and WS 1375, are highly evidenced to benefit burnout patients or subjects with work-or stress-related fatigue after repeated doses or a single dose. 220,226,229 It is demonstrated that R. rosea reduced symptoms of fatigue mainly through increasing mental performance particularly via improving attention.…”

Section: Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Rhodiola species: A comprehensive review of traditional use, phytochemistry, pharmacology, toxicity, and clinical study

Tao

Cao

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

Rhodiola species, belonging to the family Crassulaceae, have long been used as an adaptogen, tonic, antidepressant, and antistress medicine or functional food in Asia and Europe. Due to the valuable application, the growing demand of Rhodiola species has led to a rapid decrease in resource content. This review aims to summarize the integrated research progress of seven mainstream Rhodiola species. We first outline both traditional and current use of Rhodiola for the treatment of various diseases. A detailed summary and comparison of chemical, pharmacological, toxicological, and clinical studies of various Rhodiola species highlight recent scientific advances and gaps, which gives insights into the understanding of Rhodiola application and would be helpful to improve the situation of biological resources and diversities of Rhodiola plants.

show abstract

Section: Clinical Trialsmentioning

confidence: 99%

Section: Clinical Trialsmentioning

confidence: 99%

Rhodiola species: A comprehensive review of traditional use, phytochemistry, pharmacology, toxicity, and clinical study

Tao

Cao

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…A state of nonspecific resistance (SNSR) could be achieved either by the gradual “training” of an organism to withstand the effects of the stress or by adaptogens that mimic the stress. The repeated administration of adaptogens and the consequent adaptogenic or stress‐protective response arise in a manner analogous to repeated physical exercise that leads to prolonged SNSR and increased endurance and stamina . The phenomenon of adaptation to stress also underpins the hormetic response, which is defined as an adaptive response characterized by a biphasic dose–response, with a low dose that is stimulatory (i.e., has a beneficial effect) and a high dose that is inhibitory (i.e., has a toxic effect) …”

Section: The Historical Background Of the Adaptogen Conceptmentioning

confidence: 99%

Understanding adaptogenic activity: specificity of the pharmacological action of adaptogens and other phytochemicals

Panossian¹

2017

Annals of the New York Academy of Sciences

100

View full text Add to dashboard Cite

Adaptogens are stress-response modifiers that increase an organism's nonspecific resistance to stress by increasing its ability to adapt and survive. The classical reductionist model is insufficiently complex to explain the mechanistic aspects of the physiological notion of "adaptability" and the adaptogenic activity of adaptogens. Here, I demonstrate that (1) the mechanisms of action of adaptogens are impossible to rationally describe using the reductionist concept of pharmacology, whereas the network pharmacology approach is the most suitable method; and (2) the principles of systems biology and pharmacological networks appear to be more suitable for conceptualizing adaptogen function and are applicable to any phytochemical. Molecular targets, signaling pathways, and networks common to adaptogens have been identified. They are associated with stress hormones and key mediators of the regulation of homeostasis. In this context, the mechanisms of action of adaptogens are specifically related to stress-protective activity and increased adaptability of the organism. Consequently, adaptogens exhibit polyvalent beneficial effects against chronic inflammation, atherosclerosis, neurodegenerative cognitive impairment, metabolic disorders, cancer, and other aging-related diseases. Current and potential uses of adaptogens are mainly related to stress-induced fatigue and cognitive function, mental illness, and behavioral disorders. Their prophylactic use by healthy subjects to ameliorate stress and prevent age-related diseases appears to be justified. It is very unlikely that the pharmacological activity of any phytochemical is specific and associated only with one type of receptor, particularly adaptogenic compounds, which affect key mediators of the adaptive stress response at intracellular and extracellular levels of communication.

show abstract

“…Chisan ® /ADAPT-232 is a pharmaceutical formulation of a fixed combination of adaptogens Rhodiola, Eleutherococcus, and Schisandra, used in different dosage forms (capsules and the oral solution Chisan ® ) for the enhancement of mental and physical capacities in case of tiredness or during convalescence [ 37 , 38 , 39 , 40 , 41 ]. The active ingredients of Chisan ® /ADAPT-232 are extracts from Rhodiola rosea roots, Schisandra chinensis berry, and Eleutherococcus senticosus root with adaptogenic, stimulating, and stress-protective activities [ 40 , 41 , 42 ].…”

Section: Introductionmentioning

confidence: 99%

“…It has been shown that combining these three extracts in the ADAPT-232 combination induces both synergistic and antagonistic interactions of molecular networks of targeted cells, resulting in the deregulation of new genes specific exclusively for the Chisan ® /ADAPT-232 combination [ 42 ]. These interactions may influence transcriptional control of metabolic regulation both in isolated cells and on the higher levels of regulations of the entire organism [ 41 ], inducing possible benefits in COVID-19 [ 42 ] and during the recovery of patients in respiratory diseases [ 39 ]. This proposal is in line with the results of a randomized placebo control study of Chisan ® /ADAPT-232 in pneumonia [ 39 ], where Chisan ® /ADAPT-232 significantly decreased the duration of antibiotic therapy, reducing the length of the acute phase of the illness, and improving the mental performance and the quality of life of patients.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial

Karosanidze¹,

Kiladze²,

Kirtadze³

et al. 2022

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

Currently, no effective treatment of comorbid complications or COVID-19 long-haulers during convalescence is known. This randomized, quadruple-blind, placebo-controlled trial aimed to assess the efficacy of adaptogens on the recovery of patients with Long COVID symptoms. One hundred patients with confirmed positive SARS-CoV-2 test, discharged from COVID Hotel isolation, Intensive Care Unit (ICU), or Online Clinics, and who experienced at least three of nine Long COVID symptoms (fatigue, headache, respiratory insufficiency, cognitive performance, mood disorders, loss of smell, taste, and hair, sweatiness, cough, pain in joints, muscles, and chest) in the 30 days before randomization were included in the study of the efficacy of Chisan®/ADAPT-232 (a fixed combination of adaptogens Rhodiola, Eleutherococcus, and Schisandra) supplementation for two weeks. Chisan® decreased the duration of fatigue and pain for one and two days, respectively, in 50% of patients. The number of patients with lack of fatigue and pain symptoms was significantly less in the Chisan® treatment group than in the placebo group on Days 9 (39% vs. 57%, pain relief, p = 0.0019) and 11 (28% vs. 43%, relief of fatigue, * p = 0.0157). Significant relief of severity of all Long COVID symptoms over the time of treatment and the follow-up period was observed in both groups of patients, notably decreasing the level of anxiety and depression from mild and moderate to normal, as well as increasing cognitive performance in patients in the d2 test for attention and increasing their physical activity and workout (daily walk time). However, the significant difference between placebo and Chisan® treatment was observed only with a workout (daily walk time) and relieving respiratory insufficiency (cough). A clinical assessment of blood markers of the inflammatory response (C-reactive protein) and blood coagulation (D-dimer) did not reveal any significant difference over time between treatment groups except significantly lower IL-6 in the Chisan® treatment group. Furthermore, a significant difference between the placebo and Chisan® treatment was observed for creatinine: Chisan® significantly decreased blood creatinine compared to the placebo, suggesting prevention of renal failure progression in Long COVID. In this study, we, for the first time, demonstrate that adaptogens can increase physical performance in Long COVID and reduce the duration of fatigue and chronic pain. It also suggests that Chisan®/ADAPT-232 might be useful for preventing the progression of renal failure associated with increasing creatinine.

show abstract

Efficacy of Adaptogenic Supplements on Adapting to Stress: A Randomized, Controlled Trial

Cited by 10 publications

References 28 publications

Rhodiola species: A comprehensive review of traditional use, phytochemistry, pharmacology, toxicity, and clinical study

Rhodiola species: A comprehensive review of traditional use, phytochemistry, pharmacology, toxicity, and clinical study

Understanding adaptogenic activity: specificity of the pharmacological action of adaptogens and other phytochemicals

Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial

Contact Info

Product

Resources

About